## Worldwide Preclinical Co-Development Alliance for RNAi Therapy for Chronic Hepatitis B Infection

VIR-2218 (ALN-HBV02) for Treatment of HBV (10/17)

Alnylam

- \$10M upfront payment
- 1.1M Vir shares at signing plus add'l
  1.1M shs on CON dev milestone
- Equal VIR-2218 cost sharing thru POC
  - Vir pays late stage dev cost
  - \$190M in Dev/Reg milestones HBV
  - \$115M in Dev/Reg milestones add'I\*
    - \$250M in sales milestones HBV
    - \$100M in sales milestones add'l\*

ALN-HBV in Ph I/II trials in 7/16; Alnylam has option to enter 50/50 PS deal prior to Ph III start for each target

Low Double-Digit to Mid-Teen Royalty on HBV\* \* Vir elected to expand alliance into 4 add'l infectious targets in 12/19, plus any coronavirus in 3/20

\* High Single-Digit to Sub-Teen royalty for add'l targets

Vir Biotechnology

